These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

98 related articles for article (PubMed ID: 16919003)

  • 1. Dual endothelin receptor antagonism in pulmonary arterial hypertension.
    Pittrow D; Kirch W
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():v-vi. PubMed ID: 16919003
    [No Abstract]   [Full Text] [Related]  

  • 2. A new era in the management of pulmonary arterial hypertension related to scleroderma: endothelin receptor antagonism.
    Hachulla E; Coghlan JG
    Ann Rheum Dis; 2004 Sep; 63(9):1009-14. PubMed ID: 15308510
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical features and endothelin receptor antagonist in primary Sjögren's syndrome with pulmonary arterial hypertension.
    Chen CH; Chen HA; Yang KY; Yu WC; Liao HT; Huang DF
    Scand J Rheumatol; 2006; 35(3):245-7. PubMed ID: 16766376
    [No Abstract]   [Full Text] [Related]  

  • 4. Bosentan for the treatment of adult pulmonary hypertension.
    Dwyer N; Kilpatrick D
    Future Cardiol; 2011 Jan; 7(1):19-37. PubMed ID: 21174507
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Endothelin receptor antagonist bosentan. Breakthrough in the treatment of pulmonary hypertension].
    MMW Fortschr Med; 2004 Dec; 146(50):72-3. PubMed ID: 15666438
    [No Abstract]   [Full Text] [Related]  

  • 6. [PAH and many other indications. Old and new endothelin receptor antagonists.].
    Schmitz J; Holzgrabe U
    Pharm Unserer Zeit; 2010 Nov; 39(6):430-5. PubMed ID: 20967930
    [No Abstract]   [Full Text] [Related]  

  • 7. Bosentan therapy for pulmonary arterial hypertension.
    Rubin LJ; Badesch DB; Barst RJ; Galie N; Black CM; Keogh A; Pulido T; Frost A; Roux S; Leconte I; Landzberg M; Simonneau G
    N Engl J Med; 2002 Mar; 346(12):896-903. PubMed ID: 11907289
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Successful treatment of persistent pulmonary hypertension of the newborn with bosentan.
    Nakwan N; Choksuchat D; Saksawad R; Thammachote P; Nakwan N
    Acta Paediatr; 2009 Oct; 98(10):1683-5. PubMed ID: 19523174
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Bosentan].
    Taéron C
    Rev Infirm; 2005 Feb; (108):33-4. PubMed ID: 15816717
    [No Abstract]   [Full Text] [Related]  

  • 10. Thrombotic microangiopathic nephropathy, pulmonary hypertension and nephromegaly: case report of a patient treated with endothelin receptor antagonist.
    Losito A; Pittavini L; Covarelli C
    Clin Nephrol; 2012 Feb; 77(2):164-70. PubMed ID: 22257549
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bosentan for chronic thromboembolic pulmonary hypertension.
    Confalonieri M; Kodric M; Longo C; Vassallo FG
    Expert Rev Cardiovasc Ther; 2009 Dec; 7(12):1503-12. PubMed ID: 19954311
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Macitentan (Opsumit) for pulmonary arterial hypertension.
    Med Lett Drugs Ther; 2014 Feb; 56(1436):15-6. PubMed ID: 24663031
    [No Abstract]   [Full Text] [Related]  

  • 13. [Young patient with stress dyspnea of uncertain origin. Evaluate for pulmonary hypertension!].
    MMW Fortschr Med; 2002 Oct; 144(42):64. PubMed ID: 12534004
    [No Abstract]   [Full Text] [Related]  

  • 14. Endothelin and endothelin receptor antagonists in systemic rheumatic disease.
    Mayes MD
    Arthritis Rheum; 2003 May; 48(5):1190-9. PubMed ID: 12746891
    [No Abstract]   [Full Text] [Related]  

  • 15. [Endothelin].
    Maeda S; Miyauchi T; Goto K
    Nihon Rinsho; 2006 Jul; 64 Suppl 5():112-6. PubMed ID: 16895176
    [No Abstract]   [Full Text] [Related]  

  • 16. [Dyspnea. When is it pulmonary hypertension?].
    MMW Fortschr Med; 2003 Aug; 145(33-34):62. PubMed ID: 14526588
    [No Abstract]   [Full Text] [Related]  

  • 17. Bosentan.
    Chin K; Channick R
    Expert Rev Cardiovasc Ther; 2004 Mar; 2(2):175-82. PubMed ID: 15151466
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Endothelin and endothelin receptor antagonism in portopulmonary hypertension.
    Neuhofer W; Gülberg V; Gerbes AL
    Eur J Clin Invest; 2006 Sep; 36 Suppl 3():54-61. PubMed ID: 16919012
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Endothelin receptor expression in idiopathic pulmonary arterial hypertension: effect of bosentan and epoprostenol treatment.
    Hall SM; Davie N; Klein N; Haworth SG
    Eur Respir J; 2011 Oct; 38(4):851-60. PubMed ID: 21406517
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Bosentan for treatment of heart failure].
    Yoshimoto T; Hirata Y
    Nihon Rinsho; 2007 May; 65 Suppl 5():159-63. PubMed ID: 17571378
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.